WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...

This article was reviewed by Darragh O’Carroll, MD. Semaglutide Side Effects: What to Know Key takeaways: Common semaglutide ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

Oral semaglutide improved glycemic parameters and cardiovascular risk factors for adults with overweight or obesity, with ...

Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, ...

Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug ...

A drug most often prescribed for diabetes and obesity might soon be prescribed to curb one of the world’s hardest to quit ...